Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fingerprinting Single Protein Molecules for Biomarker Assisted Precision Medicine

Project description

Innovative single-molecule sensing method for protein detection

Current detection thresholds limit protein molecule sensing techniques, necessitating large sample sizes to achieve acceptable levels of sensitivity, bias, throughput, cost, and time for obtaining results. The ERC-funded SM-ProTrack project aims to develop a new single-molecule sensing method that offers unprecedented precision and detail, using silicon nano-channels on a chip and AI algorithms. This technology enables the detection of single proteins from small sample volumes. The project will apply this technology to detect biomarkers for ¬age-related macular degeneration (AMD) based on liquid biopsy, addressing a significant global need, as AMD is responsible for approximately 90 % of cases of legal blindness worldwide. It will validate the technology and establish a strong case for commercialisation.

Objective

Protein molecule sensing techniques are currently hampered by detection limits and require large samples to achieve acceptable levels of sensitivity, bias, throughput, cost, and time to result. Leveraging findings from our NanoProt-ID (ADG ERC), in SM-ProTrack we will develop a novel single-molecule sensing method with unprecedented levels of detail and accuracy. This technology is based on the separation of molecules using silicon nano-channels on a chip, tracking of single molecules, and high-precision identification using AI algorithms. Thus, the technology allows detection of multiplexed, full-length single proteins, from extremely small sample volumes, in a low-cost, portable device.
Here, to advance the clinical relevancy of the technology and build specific commercial value, we will apply it towards Age-related Macular Degeneration (AMD) sensing based on liquid biopsy. AMD represents 90% of cases of legal blindness globally, affecting ~200 million people’s life quality. To date, a quantitative sensing of AMD biomarkers, has not been possible due to the extremely small volumes of the clinical eye-derived aqueous humour (AH) sample and low abundance of the AMD biomarkers. In collaboration with a leading AMD ophthalmologist, SM-ProTrack will advance the technology to proof-of-principle validation, hence building a solid commercialization case while addressing an unmet global need.
SM-ProTrack will pave the way for a low-cost, highly sensitive technology for single protein molecule sensing, that can provide rapid and accurate results from dilute and small clinical sample volumes with minimal biases. Validated in the field of AMD biomarkers, our technology can be further applied in many other liquid biopsy diagnostics fields.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Net EU contribution
€ 150 000,00
Address
SENATE BUILDING TECHNION CITY
32000 Haifa
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)